Zymeworks Inc. (ZYME) SEC Filing 8-K Material Event for the period ending Monday, August 1, 2022

Zymeworks Inc.

CIK: 1403752 Ticker: ZYME

View differences made from one to another to evaluate Zymeworks Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Zymeworks Inc..


Assess how Zymeworks Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Zymeworks Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Zymeworks Inc. provided additional information to their SEC Filing as exhibits

Ticker: ZYME
CIK: 1403752
Form Type: 8-K Corporate News
Accession Number: 0001193125-22-209067
Submitted to the SEC: Mon Aug 01 2022 6:48:01 PM EST
Accepted by the SEC: Tue Aug 02 2022
Period: Monday, August 1, 2022
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: